StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report sent to investors on Friday. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial lowered their target price on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Fresenius Medical Care currently has a consensus rating of Hold and a consensus target price of $22.00.

Fresenius Medical Care Trading Down 0.8 %

FMS opened at $19.68 on Friday. The company has a fifty day moving average price of $19.33 and a two-hundred day moving average price of $19.85. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $23.29. The company has a market cap of $11.55 billion, a P/E ratio of 22.11, a price-to-earnings-growth ratio of 1.03 and a beta of 0.90. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care (NYSE:FMS) last issued its earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. Analysts predict that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

A number of large investors have recently bought and sold shares of FMS. Mercer Global Advisors Inc. ADV raised its stake in Fresenius Medical Care by 4.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after acquiring an additional 624 shares during the period. Signaturefd LLC raised its position in shares of Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares during the period. GAMMA Investing LLC lifted its stake in shares of Fresenius Medical Care by 21.8% during the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after buying an additional 758 shares in the last quarter. Ritholtz Wealth Management boosted its holdings in Fresenius Medical Care by 2.5% in the 2nd quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock worth $704,000 after buying an additional 895 shares during the period. Finally, Rhumbline Advisers grew its stake in Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after buying an additional 1,128 shares in the last quarter. 8.25% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.